H
Henlius Biopharmaceuticals
Sustainability Report and Carbon Intensity Rankings
Is Henlius Biopharmaceuticals doing their part?
Their DitchCarbon score is 51
Henlius Biopharmaceuticals has a DitchCarbon Score of 51, indicating a moderate level of sustainability in their operations. This score reflects the company’s carbon intensity, which is a measure of how much carbon emissions are produced relative to their activity. A score of 51 suggests that Henlius Biopharmaceuticals is making progress but still has room for improvement in reducing its carbon footprint.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Henlius Biopharmaceuticals is part of the research and development sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Unknown
High
Very high
Henlius Biopharmaceuticals, located in China, operates in a region with a specific carbon intensity rating. The sustainability of the company’s operations is influenced by China’s overall carbon intensity, affecting its environmental impact.
Unlock 30+ emissions data points on Henlius Biopharmaceuticals
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Henlius Biopharmaceuticals
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
0.36%
...this company is doing 0.36% worse in emissions than the industry average.
Henlius Biopharmaceuticals, Inc., founded in the research and development sector, is a biotechnology firm based in Fremont, California, United States. Established at 48860 Milmont Drive, the company specializes in the discovery and development of innovative biopharmaceuticals. Henlius offers a range of services including drug development, clinical trials, and the commercialization of therapeutic antibodies.
emission intelligence's platform recommendations for Henlius Biopharmaceuticals
Henlius Biopharmaceuticals should undertake a thorough inventory of all Scope 1 emissions sources to identify and mitigate direct greenhouse gas emissions.
Bad news, Henlius Biopharmaceuticals hasn't committed to SBTi yet
Henlius Biopharmaceuticals has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company is either in the process of setting or has not publicly disclosed its goals for reducing greenhouse gas emissions in line with climate science.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.